H R Shinefield

Summary

Affiliation: Kaiser Permanente
Country: USA

Publications

  1. ncbi Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis
    Henry Shinefield
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    N Engl J Med 346:491-6. 2002
  2. ncbi Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
    H R Shinefield
    Kaiser Permanente Pediatric Vaccine Study Center of Northern California, Oakland, USA
    Pediatr Infect Dis J 18:757-63. 1999
  3. ncbi Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children
    Henry R Shinefield
    Kaiser Permanente Vaccine Study Group, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:555-61. 2002
  4. ncbi Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants
    Henry Shinefield
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:182-6. 2002
  5. ncbi Varicella serology among school age children with a negative or uncertain history of chickenpox
    T A Lieu
    Division of Research, Pediatric Vaccine Study Center, Kaiser Permanente, Oakland, CA 94611, USA
    Pediatr Infect Dis J 17:120-5. 1998
  6. ncbi Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX
    H R Shinefield
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94115, USA
    Pediatr Infect Dis J 17:980-5. 1998
  7. ncbi Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers
    S B Black
    Pediatric Vaccine Study Group, Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 16:53-8. 1997
  8. ncbi Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente
    S Black
    Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaze 16th floor, Oakland, CA 94612, USA
    Vaccine 19:S83-6. 2000
  9. ncbi The hidden costs of infant vaccination
    T A Lieu
    Division of Research, Kaiser Permanente, Oakland, CA, USA
    Vaccine 19:33-41. 2000
  10. ncbi Efficacy of pneumococcal conjugate vaccines in large scale field trials
    H R Shinefield
    Vaccine Study Center, Kaiser Permanente Vaccine Study Center, Oakland, CA 94611, USA
    Pediatr Infect Dis J 19:394-7. 2000

Detail Information

Publications33

  1. ncbi Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis
    Henry Shinefield
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    N Engl J Med 346:491-6. 2002
    ..The capsular polysaccharides are essential for the pathogenesis of and immunity to S. aureus infection and are targets for vaccines...
  2. ncbi Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers
    H R Shinefield
    Kaiser Permanente Pediatric Vaccine Study Center of Northern California, Oakland, USA
    Pediatr Infect Dis J 18:757-63. 1999
    ....
  3. ncbi Vaccination with measles, mumps and rubella vaccine and varicella vaccine: safety, tolerability, immunogenicity, persistence of antibody and duration of protection against varicella in healthy children
    Henry R Shinefield
    Kaiser Permanente Vaccine Study Group, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:555-61. 2002
    ....
  4. ncbi Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants
    Henry Shinefield
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:182-6. 2002
    ..To determine the efficacy, immunogenicity and safety of the heptavalent CRM197 pneumococcal conjugate vaccine (PCV) in low birth weight (LBW) and preterm (PT) infants against invasive pneumococcal disease caused by vaccine types...
  5. ncbi Varicella serology among school age children with a negative or uncertain history of chickenpox
    T A Lieu
    Division of Research, Pediatric Vaccine Study Center, Kaiser Permanente, Oakland, CA 94611, USA
    Pediatr Infect Dis J 17:120-5. 1998
    ..Our main objective was to describe varicella seroprevalence among children ages 7 to 12 years with a negative or uncertain history of chickenpox...
  6. ncbi Safety, tolerability and immunogenicity of concomitant injections in separate locations of M-M-R II, VARIVAX and TETRAMUNE in healthy children vs. concomitant injections of M-M-R II and TETRAMUNE followed six weeks later by VARIVAX
    H R Shinefield
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94115, USA
    Pediatr Infect Dis J 17:980-5. 1998
    ..Local and systemic adverse reactions were recorded. Exposure and cases of varicella were documented through a 1-year follow-up period...
  7. ncbi Safety and immunogenicity of Chiron/Biocine recombinant acellular pertussis-diphtheria-tetanus vaccine in infants and toddlers
    S B Black
    Pediatric Vaccine Study Group, Kaiser Permanente Vaccine Study Center, Oakland, CA, USA
    Pediatr Infect Dis J 16:53-8. 1997
    ..To evaluate the safety and immunogenicity of the recombinant acellular pertussis-diphtheria-tetanus (aPDT) vaccine (C-aPDT, Chiron/Biocine)...
  8. ncbi Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente
    S Black
    Kaiser Permanente Vaccine Study Center, 1 Kaiser Plaze 16th floor, Oakland, CA 94612, USA
    Vaccine 19:S83-6. 2000
    ..Vaccination of healthy infants would result in net savings for society if the vaccine cost less than $46 per dose, and net savings for the health care payer if the vaccine cost less than $18 per dose...
  9. ncbi The hidden costs of infant vaccination
    T A Lieu
    Division of Research, Kaiser Permanente, Oakland, CA, USA
    Vaccine 19:33-41. 2000
    ..The financial costs of medical utilization and work-loss resulting from common vaccine-associated symptoms are non-negligible and should be incorporated in economic analyses...
  10. ncbi Efficacy of pneumococcal conjugate vaccines in large scale field trials
    H R Shinefield
    Vaccine Study Center, Kaiser Permanente Vaccine Study Center, Oakland, CA 94611, USA
    Pediatr Infect Dis J 19:394-7. 2000
    ....
  11. ncbi Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccine
    S B Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 20:1105-7. 2001
    ..To evaluate the impact of the introduction and routine use of seven valent pneumococcal conjugate vaccine on the epidemiology of invasive pneumococcal disease within the Northern California Kaiser Permanente (KP) population...
  12. ncbi Variation in clinician recommendations for multiple injections during adoption of inactivated polio vaccine
    T A Lieu
    Division of Research and the Vaccine Study Center, Kaiser Permanente, Oakland, California, USA
    Pediatrics 107:E49. 2001
    ....
  13. ncbi Safety of neonatal hepatitis B vaccine administration
    E Lewis
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94610, USA
    Pediatr Infect Dis J 20:1049-54. 2001
    ..In addition our data did not support any increase in medical procedures attributed to receipt of hepatitis B vaccine...
  14. ncbi Impact of maternal influenza vaccination during pregnancy on the incidence of acute respiratory illness visits among infants
    Eric K France
    Department of Preventive Medicine and Clinical Research Unit, Kaiser Permanente Colorado, Denver, CO 80231, USA
    Arch Pediatr Adolesc Med 160:1277-83. 2006
    ..To determine whether influenza vaccination of pregnant women prevents visits for respiratory illness in their infants born during the influenza season...
  15. ncbi Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible?
    Henry R Shinefield
    Pediatrics and Dermatology, University of California, San Francisco, 400 Parnassus Avenue, San Francisco, CA 94143, USA
    Vaccine 24:S2-65-9. 2006
    ..In particular, the success of a Phase 3 clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 is discussed...
  16. ncbi Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine
    Arnd M Herz
    Department of Pediatrics and Pediatric Infectious Disease, Kaiser Permanente, Hayward, CA 94545, USA
    Pediatr Infect Dis J 25:293-300. 2006
    ..The introduction of routine vaccination with heptavalent conjugated pneumococcal vaccine has changed the overall incidence of bacteremia in children 3 months-3 years old...
  17. ncbi Prospects for active and passive immunization against Staphylococcus aureus
    Henry R Shinefield
    University of California, San Francisco, CA, USA
    Pediatr Infect Dis J 25:167-8. 2006
  18. ncbi Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine
    Timo Vesikari
    University of Tampere Medical School, Tampere, Finland
    N Engl J Med 354:23-33. 2006
    ..The risk of intussusception was similar in vaccine and placebo recipients. (ClinicalTrials.gov number, NCT00090233.)..
  19. ncbi Prevention of Staphylococcus aureus infections: advances in vaccine development
    Henry R Shinefield
    University of California School of Medicine, San Francisco, CA 94109, USA
    Expert Rev Vaccines 4:669-76. 2005
    ..In particular, the results of a Phase III clinical study of a vaccine directed at capsular polysaccharides types 5 and 8 are discussed...
  20. ncbi Safety of the trivalent inactivated influenza vaccine among children: a population-based study
    Eric K France
    Clinical Research Unit, Kaiser Permanente Colorado, Denver, USA
    Arch Pediatr Adolesc Med 158:1031-6. 2004
    ..To our knowledge, there are no published population-based studies on the safety of the inactivated trivalent influenza vaccine among children...
  21. ncbi Effectiveness of influenza vaccine during pregnancy in preventing hospitalizations and outpatient visits for respiratory illness in pregnant women and their infants
    Steven B Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Am J Perinatol 21:333-9. 2004
    ..Hospitalizations for respiratory illness were uncommon in both vaccinees and nonvaccinees...
  22. ncbi Pneumococcal conjugate vaccine in children
    Robert L Davis
    N Engl J Med 350:84-5; author reply 84-5. 2004
  23. ncbi Vaccinations and risk of central nervous system demyelinating diseases in adults
    Frank Destefano
    National Immunization Program, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Arch Neurol 60:504-9. 2003
    ..Several case reports of the onset or exacerbation of multiple sclerosis or other demyelinating conditions shortly after vaccination have suggested that vaccines may increase the risk of demyelinating diseases...
  24. ncbi Observed costs and health care use of children in a randomized controlled trial of pneumococcal conjugate vaccine
    G Thomas Ray
    Division of Research, Kaiser Permanente Medical Care Program, Oakland, CA 94611, USA
    Pediatr Infect Dis J 21:361-5. 2002
    ..Pneumococcal conjugate vaccine for infants has recently been found to be effective for prevention of meningitis, bacteremia, pneumonia and otitis media, but it is more costly than previously introduced vaccines...
  25. ncbi Lack of association between receipt of conjugate haemophilus influenzae type B vaccine (HbOC) in infancy and risk of type 1 (juvenile onset) diabetes: long term follow-up of the HbOC efficacy trial cohort
    Steven B Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:568-9. 2002
    ..These children are now 10 to 12 years of age. We found no evidence that vaccination with Hib conjugate vaccine in infancy is associated with risk of diabetes later in life...
  26. ncbi Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia
    Steven B Black
    Kaiser Permanente Vaccine Study Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 21:810-5. 2002
    ..To determine the effectiveness of the Wyeth heptavalent pneumococcal conjugate vaccine against clinical and radiograph-confirmed pneumonia in children...
  27. ncbi Hepatitis B vaccination among adolescents in 3 large health maintenance organizations
    Idalia M Gonzalez
    Epidemiology Program Office, National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Pediatrics 110:929-34. 2002
    ..Little is known about the implementation of these recommendations in a managed care setting. The objective of this study was to determine the impact of ACIP recommendations on HB vaccination among adolescents in 3 managed care settings...
  28. ncbi Impact of the pneumococcal conjugate vaccine on otitis media
    Bruce Fireman
    Kaiser Permanente Division of Research and the Kaiser Permanente Vaccine Studies Center, Oakland, CA 94612, USA
    Pediatr Infect Dis J 22:10-6. 2003
    ..The heptavalent pneumococcal conjugate vaccine (PCV) is recommended for infants to protect against invasive disease, but its impact on otitis might also have public health importance...
  29. ncbi Polio extraimmunization in children younger than 2 years after changes in immunization recommendations
    Loren K Mell
    Center for Health Studies, Group Health Cooperative, Seattle, Washington, USA
    Pediatrics 111:296-301. 2003
    ..CONCLUSIONS: Poliovirus extraimmunization rates have fallen dramatically in association with the change-over to the all inactivated polio virus schedule...
  30. ncbi Varicella immunogenicity with 1- and 2-dose regimens of measles-mumps-rubella-varicella vaccine
    Henry R Shinefield
    Department of Pediatrics, University of California at San Francisco School of Medicine, San Francisco, California, USA
    J Infect Dis 197:S152-5. 2008
    ....
  31. ncbi Compliance with national immunization guidelines for children younger than 2 years, 1996-1999
    Loren K Mell
    Center for Health Studies, Group Health Cooperative, Seattle, Washington, USA
    Pediatrics 115:461-7. 2005
    ..6% of children were compliant with prevailing childhood immunization recommendations from 1996 to 1999. Efforts to improve compliance with guidelines are recommended, to optimize childhood infectious disease prevention...
  32. ncbi Childhood vaccinations and risk of asthma
    Frank Destefano
    Centers for Disease Control and Prevention, Atlanta, GA, USA
    Pediatr Infect Dis J 21:498-504. 2002
    ..The weak associations for Hib and hepatitis B vaccines seem to be at least partially accounted for by health care utilization or information bias...
  33. ncbi Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old
    Simon J Hambidge
    Clinical Research Unit, Kaiser Permanente Colorado, Denver, CO 80237 8066, USA
    JAMA 296:1990-7. 2006
    ..Beginning with the winter season of 2004-2005, influenza vaccination has been recommended for all children 6 to 23 months old in the United States. However, its safety in young children has not been adequately studied in large populations...